Celebrating 50 Years of DSCH: Prognostic Power, Predictive Promise & Patient Progress in Oncology

Marking 50 years of the Danish Society for Cyto- and Histochemistry (DSCH), this Anniversary symposium is more than a scientific meeting: it is a celebration of collaboration, discovery, and the future of biomarkers in oncology.

 

Venue: Auditorium 2, Entrance 44, Rigshospitalet Blegdamsvej 9, 2100 København Ø
Date: 21 May 2026 13.00 – 18.00

Language: English
Moderator: Christian Beltoft Brøchner, MD, PhD, Department of Pathology, Rigshospitalet

 

Program

13:00 – 13:05 | Welcome by DSCH, Kristian Egebjerg, MD, Department of Oncology, Rigshospitalet

13:05 – 13:30 | Block 1: Definitions of biomarkers

  • Clinical examples of prognostic and predictive Biomarkers in Oncology (Morten Mau Sørensen, MD, PhD, Consultant, Department of Oncology Rigshospitalet)

13:30 – 15:00 | Block 2: Regulators’ perspectives: New Oncological Drugs in Denmark – Drug-Diagnostic Combinations

  • EMA regulatory aspects of drug and companion diagnostic combinations. (Harald Enzmann, MD, MS, Former CHMP Chair European Medical Agency, Section Head European and International Affairs BfArM)
  • Regulatory requirements for companion diagnostics and updates on the implementation of IVDR in Denmark (Jeppe Larsen, MS, Director of Medical Devices Danish Medical Agency)
  • The Role of Biomarkers in Oncology Therapeutic Approvals (TBA, Danish Medicines Council)
  • Panel discussion & Q&A

15:00 – 15:20 | Coffee break

15:20 – 16:15 | Block 3: HER2 as a Success Story and the Way Forward

  • HER2 Testing: A Success Story and the Ongoing Challenge of Reproducibility (Anne-Vibeke Lænkholm, MD, DMSc, Consultant Pathologist & Associate Professor, Herlev – Gentofte Hospital)
  • Algorithms in Action: Digital Tools for Biomarker evaluation (Jeppe Thagaard, Scientific Director, & Niklas Petersen, New Business Account Executive, Visiopharm)
  • Panel discussion & Regulatory reflection: Implementation of automated/AI-based HER2 scoring

16:15 – 16:35 | Coffee break

16:35 – 17:30 | Block 4: Complex Signatures vs Single-Marker Diagnostics

  • Multi-parameter signatures & data integration (Frederik Otzen Bagger, MS, PhD, Head of Bioinformatics Genomic Medicine Rigshospitalet)
  • RNA-signatures for treatment decisions (AIDA Oncology)
  • Panel discussion & Regulatory reflection: How to regulate complex signatures vs single markers

17:35 – 18:00 | Closing & celebration 

 

Registration is free of charge. Seating is limited, and registration closes on 14 May or once capacity has been reached.

 

On behalf of the Board of DSCH:

Kristian Egebjerg, Karina Hjort,

Tove Kirkegaard Clausen, Filis Necip &

Jan Trøst Jørgensen